CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure
Public ClinicalTrials.gov record NCT06569082. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
CD34+ Selected Donor Cell Boost for Management of Poor Graft Function or Primary or Secondary Graft Failure Following Allogeneic Hematopoietic Stem Cell Transplantation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The proposed trial is a single arm, non-randomized, single center pilot study utilizing CliniMACS CD34 Reagent System for patients following allogeneic hematopoietic stem cell transplant (HSCT) requiring treatment of graft dysfunction or failure.
Study identification
- NCT ID
- NCT06569082
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 21 participants
Conditions and interventions
Conditions
Interventions
- Blood Stem Cell Infusion Procedure
- CD34+ Selected Donor Cell Boost Device
Procedure · Device
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 30, 2024
- Primary completion
- Jul 31, 2034
- Completion
- Jul 31, 2035
- Last update posted
- Sep 28, 2025
2024 – 2035
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| NYU Langone Health | New York | New York | 10016 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Graft Failure trials
Other public records listing Graft Failure. Sorted by last update posted; newest first. Not a recommendation.
- NCT07252050: Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease Recruiting
- NCT06872333: Allo HSCT for High Risk Hemoglobinopathies Recruiting
- NCT04967391: Tumescence in HNC Skin Graft Reconstruction Active, not recruiting
- NCT07244419: Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients Recruiting
- NCT05084768: Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06569082, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 28, 2025 · Synced Jul 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06569082 live on ClinicalTrials.gov.